GlobalData, a research and consulting firm, reported that the global Rheumatoid Arthritis (RA) treatment market value will witness steady growth, from $15.6 billion in 2013 to $19.3 billion in 2023.
GlobalData believes that the market expansion for RA treatment over the coming decade will be driven by increased RA prevalence, as well as the anticipated launches of novel drugs.
Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory disease that causes pain, swelling, stiffness and loss of function in the joints.
Advertisement
The products include three interleukin-6 inhibitors, four biologics novel to the RA market, four Janus kinase (JAK) inhibitors, and numerous biosimilars.
Heather Leach, Ph.D., GlobalData's Analyst covering Immunology, said, "Drugs with novel mechanisms of action, including biologics and small molecules, are welcome additions to the RA therapeutics market. However, this arena will become increasingly crowded over the next decade."
![Diet, Nutrition and Supplements for Osteo-Arthritis and Rheumatoid Arthritis]( "Diet, Nutrition and Supplements for Osteo-Arthritis and Rheumatoid Arthritis")
Rheumatoid arthritis patients should consume a diet rich in natural antioxidant and anti-inflammatory nutrients and avoid foods like sugar, saturated fats, and trans fatty acids.
RA is an attractive therapy area for pharmaceutical companies as it is dominated by expensive biologics, and oral JAK inhibitors entering the market are expected to be priced only at a slight discount.
Perhaps the most anticipated event in the RA space is the addition of biosimilars, which are assumed to be priced at a 30% discount to the reference product.
Leach added that while the launch of biosimilars will provide a less expensive therapy option for patients, their lack of regulatory guidelines would delay their availability in a number of regions.
The company's latest report states that US boasts the largest RA treatment space, with a 67% share in 2013 among the 10 major pharmaceutical markets (the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China, and India).
Source: Medindia
Diet, Nutrition and Supplements for Osteo-Arthritis and Rheumatoid Arthritis
Rheumatoid arthritis patients should consume a diet rich in natural antioxidant and anti-inflammatory nutrients and avoid foods like sugar, saturated fats, and trans fatty acids.
Advertisement
RA is an attractive therapy area for pharmaceutical companies as it is dominated by expensive biologics, and oral JAK inhibitors entering the market are expected to be priced only at a slight discount.
Perhaps the most anticipated event in the RA space is the addition of biosimilars, which are assumed to be priced at a 30% discount to the reference product.
Leach added that while the launch of biosimilars will provide a less expensive therapy option for patients, their lack of regulatory guidelines would delay their availability in a number of regions.
The company's latest report states that US boasts the largest RA treatment space, with a 67% share in 2013 among the 10 major pharmaceutical markets (the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China, and India).
Source: Medindia
Physiotherapy for Arthritis
Physiotherapy enables patients with debilitating disease to regain loss of function in their muscles, and joints. Physiotherapy for rheumatoid arthritis involves electrostimulation and hydrotherapy.
Advertisement
 Tests for Rheumatoid ArthritisAre you experiencing pain in the joints? You might have Rheumatoid arthritis, a condition affecting joints and results in pain and joint deformities. It is diagnosed by radiology and blood tests. | Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
In myeloma (blood cancer) cells, cancer-promoting potential of the fatty acid binding proteins was found to determine to be a valid target for myeloma therapeutics
Acute liver failure cases dropped after the Food and Drug Administration rule to lower the dosage of acetaminophen